CIDRAP Antimicrobial Stewardship Project Newsletter – Jun 25, 2020


In this week's issue:

  • What's new at CIDRAP-ASP
  • AMR research and the UN SDGs
  • Substandard antibiotics, AMR, and COVID-19
  • Next steps for global AMR surveillance
  • High carbapenem-non–susceptible Acinetobacter rates in Europe
  • VABP in French COVID-19 patients
  • Antibiotic use education for young children
  • Pharmacist-led antimicrobial management for COVID-19 patients
  • Community engagement on AMR in low-income settings
  • Integration of antibiogram data with prescribing guidelines in emergency care
  • Antibiotic consumption, quality, and accessibility in India
  • Risk for invasive aspergillosis in COVID-19 patients




[Register] Registration is open for our free Jun 30 webinar on "Improving Antimicrobial Prescribing in Companion Animal Medicine," featuring a presentation and question-and-answer session from Jennifer Granick, DVM, PhD, and Emma Leof, MPH.


[Connect] On NPR's Fresh Air, host Terry Gross speaks with CIDRAP-ASP Director Michael Osterholm, PhD, MPH, about risk and uncertainty surrounding US states' decisions to reopen, governmental responses to a public health emergency, concerns surrounding antimicrobial resistance (AMR), along with more timely issues.


[Weigh In] Take our June quiz to gauge your knowledge on the challenges and opportunities that COVID-19 presents to antimicrobial stewardship. And to learn more, read a recent CIDRAP News story on how clinicians are making decisions about antibiotic use for COVID-19 patients.


[Read] CIDRAP News recently published stories on a higher risk of death associated with outpatient use of azithromycin compared to amoxicillin, a novel drug-resistant meningococcus strain in the US and much more.


[Research] Please take a moment to visit our recently launched resource hub on COVID-19 and antimicrobial stewardship, our compendium of databases and tools for AMR surveillance, our antimicrobial stewardship diagnostics resources, our database containing hundreds of publicly available clinical tools for antimicrobial stewardship programs, and our educational multimedia page. The surveillance and diagnostics pages are updated at least weekly, and we add new clinical and educational tools monthly.


[Stay Current] If you'd like to stay current on all our news and events, please follow CIDRAP-ASP on Twitter and Facebook, subscribe to our YouTube channel, and subscribe to our antimicrobial stewardship podcasts on iTunes or Spotify.




[Listen] In a Microbiology Society "Microbe Talk" podcast, host Emily Parr, PhD, MSc, speaks with Laura Piddock, PhD, and Anne Leonard, PhD, MSc, about the applicability of AMR research to the United Nations Sustainable Development Goals.


[Rethink] In commentary for the United States Pharmacopeial Convention (USP), Carly Ching, PhD, and Muhammad Hamid Zaman, PhD, describe concerns around substandard and falsified antibiotics and the rise of AMR during the COVID-19 pandemic.


[Peruse] ReAct reflects on the World Health Organization's brief report on the Global AMR Surveillance System (GLASS), focusing on increasing enrollment, caveats around data interpretation, global rises in resistance to important antibiotics, and the importance of surveillance to AMR efforts.


[Examine] In Antimicrobial Resistance & Infection Control, Olaniyi Ayobami, MBBS, MSc, et al assess data on 18,412 invasive Acinetobacter species isolates obtained across 30 European countries from 2013 to 2017, finding a 35.6% rate of carbapenem non-susceptibility across Europe, with particularly high rates of 75.5% and 71.5% in southern and eastern Europe, respectively.


[Engage] In an interview for Canada's CBC News, Amina Zafar, MMJC, discusses concerns raised by Eric Brown, PhD, about long-term effects from antibiotic overuse during the COVID-19 pandemic.


[Analyze] In Clinical Infectious Diseases, Emmanuel Dudoignon, MD, et al describe 20 cases of bacterial pneumonia in COVID-19 patients receiving care in a French intensive care unit, noting that 15 cases were ventilator-associated pneumonias (VAP), with early-onset VAP associated with gram-positive bacteria and late-onset VAP associated with gram-negative pathogens.


[View] The Food and Agriculture Organization of the United Nations (FAO) North America office and the Embassy of Denmark in the USA have made available a recording of a meeting to address the need for a One Health approach to addressing AMR during the COVID-19 pandemic.


[Study] News from the NHS Wales University Health Board highlights the work of antimicrobial pharmacist Kailey Sassi-Jones in developing educational modules about appropriate antibiotic use and infection prevention for children in elementary and home schools.


[Evaluate] In Infection Control & Hospital Epidemiology, K. Ashley Jones, PharmD, et al discuss a US hospital's use of surveillance software and protocols to incorporate SARS-CoV-2 test results into pharmacists' review of antimicrobial use and provide a mechanism for pharmacists to reduce opportunities for clinician exposure to COVID-19 patients.


[Discover] ReAct features an interview with Jessica Mitchell, PhD, about the role of community engagement and empowerment in helping to develop approaches to AMR in low-income settings.


[Explore] In the Philadelphia Inquirer, Kasra Zarei describes factors that may contribute to the risk of drug-resistant bacterial infections in COVID-19 patients.


[Assess] In the Journal of Pharmacy Practice, Kristin Stoll, PharmD, et al evaluate algorithms that integrate antibiogram data with prescribing guidelines for community-acquired pneumonia, skin and other soft-tissue infections, and urinary tract infections in a US emergency department, finding that the algorithms were associated with improved selection of an appropriate antimicrobial, dose, and duration of therapy, as well as reduced rates of fluoroquinolone use.


[Learn] On DownToEarth, Kundan Pandey, MA, discusses recent research on the prevalence of AMR and how drug resistance is affecting patient treatment, with particular attention to antibiotic consumption, quality, and accessibility in India.


[Review] In Open Forum Infectious Diseases, George R. Thompson, III, MD, et al discuss the available data that suggest an under-recognized risk for invasive aspergillosis in COVID-19 patients, arguing for improved data collection, study design, and autopsy screening across global networks. And in Clinical Infectious Diseases, Robby Nieuwlaat, PhD, MSc, et al outline the need for data that might further an understanding of the COVID-19 pandemic's long-term effects on AMR.

newsletter signupfacebooklinked intwitteremail alerts
Contact Us

Center for Infectious Disease Research and Policy
Academic Health Center, University of Minnesota, Minneapolis, MN
© CIDRAP 2020 Regents of the University of MN
Academic Health Center, University of MN